XPeng Backed HT Aero Unveils Flying Vehicle City Usage Scenarios
24.9.2021 08:58:00 EEST | Business Wire | Press release
HT Aero, an urban air mobility (UAM) company in which XPeng Inc. is an investor, today unveiled future urban usage scenarios for its fifth-generation flying vehicle XPeng X2 ("X2"), including autonomous flight take-off and landing for specific city scenarios, back-end scheduling, charging and flight control.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923006034/en/
XPeng X2 flying vehicle (Photo: Business Wire)
XPeng X2 will present at the 13th Airshow China 2021, starting on September 28 in Zhuhai, Guangdong Province.
X2 is equipped with a robust, highly intelligent flight control system and superior autonomous flying capability, able to conduct autonomous flight route planning, all-round real-time imaging, real-time flight monitoring, two-way real-time communications, all-round environmental perception and autonomous return and landing. It is powered by a highly efficient and convenient charging system, leveraging XPeng’s supercharging technology.
The X2 has an user-friendly interface with one-key start, one-key return, and one-key landing, significantly reducing burdens for the user, delivering a safe and intelligent flight experience.
Before take-off, the system performs intelligent autonomous flight route planning based on the destination entered by the user, comprehensively evaluating factors such as surrounding buildings, no-fly and restricted areas, and weather conditions.
In a graphical recreational video, X2 demonstrates an efficient, effective and environmentally friendly commute from the top apron of a CBD building to a residential building, and connecting to the airport and other transportation hubs, simulating future lifestyle, business travel and other mobility scenarios.
In its first debut at an aerospace exhibition, X2 will be shown on September 28 at the 13th China International Aviation & Aerospace Exhibition (Airshow China 2021), showcasing its cutting-edge design and capabilities.
Introducing XPeng X2, the 5th generation flying vehicle
The XPeng X2 is the latest generation flying vehicle independently developed by HT Aero, having conducted more than 15,000 safe, manned flights. X2 is a pure electric two-seater enclosed-cockpit flying vehicle and an exploration of an aircraft-car integration with significantly improved effective load, passenger number, exterior design and flight control system than the previous generation.
X2 adopts a closed cockpit for the first time, with styling that shares the design language of the XPeng P7. It presents an elegant, minimalist and a teardrop profile. As well as its sci-fi appearance, X2 also takes into account high-efficiency aerodynamics to optimize flight performance.
With a full carbon fiber structure, X2 weighs 560 kilograms (empty aircraft with battery) and has the maximum take-off weight of 760 kilograms with a capacity of two passengers. It can cruise at a maximum design speed of 130 kilometers per hour and has a range of 35 minutes at a designed flying height of under 1,000 meters, suitable for low-altitude urban flight scenarios.
Powered purely by electricity, X2 has no carbon dioxide emissions during flight, in line with the company’s goal of green urban transportation. With 130 kilometers per hour, X2 can meet the needs of short-distance urban transportation, and can serve in scenarios such as air patrol, field rescue, and medical transportation.
About HT Aero
HT Aero aspires to be the leading pioneer of urban air mobility (UAM) and is dedicated to producing safe and intelligent electric flying vehicles which combine automotive and aerospace technologies to realize domestic air-travel usage at scale. Jointly funded and controlled by Mr. He Xiaopeng, XPeng Inc. and ZHAO Deli, HT Aero has a team of highly experienced R&D associates in multiple disciplines such as avionics, test flight, airworthiness, safety, structural mechanics, industrial design and embedded systems. Established in 2013, it has accumulated 15,000 safe, manned flight experiences. For more information, please visit https://www.aeroht.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923006034/en/
Contact information
Marie Cheung
mariecheung@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
